These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 24574044

  • 1. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.
    Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, Ishigaki Y, Kitada M, Srivastava SP, Koya D.
    Diabetes; 2014 Jun; 63(6):2120-31. PubMed ID: 24574044
    [Abstract] [Full Text] [Related]

  • 2. Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition.
    Shi S, Srivastava SP, Kanasaki M, He J, Kitada M, Nagai T, Nitta K, Takagi S, Kanasaki K, Koya D.
    Kidney Int; 2015 Sep; 88(3):479-89. PubMed ID: 25830763
    [Abstract] [Full Text] [Related]

  • 3. Linagliptin but not Sitagliptin inhibited transforming growth factor-β2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition.
    Shi S, Kanasaki K, Koya D.
    Biochem Biophys Res Commun; 2016 Feb 26; 471(1):184-90. PubMed ID: 26826382
    [Abstract] [Full Text] [Related]

  • 4. DPP-4 inhibitors-renoprotection in diabetic nephropathy?
    Panchapakesan U, Pollock CA.
    Diabetes; 2014 Jun 26; 63(6):1829-30. PubMed ID: 24853893
    [No Abstract] [Full Text] [Related]

  • 5. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
    Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, Raila J, Henze A, Klein T, Hocher B.
    Kidney Blood Press Res; 2012 Jun 26; 36(1):119-30. PubMed ID: 23171828
    [Abstract] [Full Text] [Related]

  • 6. Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
    Darsalia V, Olverling A, Larsson M, Mansouri S, Nathanson D, Nyström T, Klein T, Sjöholm Å, Patrone C.
    Regul Pept; 2014 May 26; 190-191():25-31. PubMed ID: 24821550
    [Abstract] [Full Text] [Related]

  • 7. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.
    Schürmann C, Linke A, Engelmann-Pilger K, Steinmetz C, Mark M, Pfeilschifter J, Klein T, Frank S.
    J Pharmacol Exp Ther; 2012 Jul 26; 342(1):71-80. PubMed ID: 22493041
    [Abstract] [Full Text] [Related]

  • 8. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
    Kanasaki K.
    Clin Sci (Lond); 2018 Feb 28; 132(4):489-507. PubMed ID: 29491123
    [Abstract] [Full Text] [Related]

  • 9. Hibiscus sabdariffa polyphenols alleviate insulin resistance and renal epithelial to mesenchymal transition: a novel action mechanism mediated by type 4 dipeptidyl peptidase.
    Peng CH, Yang YS, Chan KC, Wang CJ, Chen ML, Huang CN.
    J Agric Food Chem; 2014 Oct 08; 62(40):9736-43. PubMed ID: 25226384
    [Abstract] [Full Text] [Related]

  • 10. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, Hirota D, Ono T, Usui HK, Makino H.
    Biochem Biophys Res Commun; 2014 Jan 17; 443(3):828-33. PubMed ID: 24342619
    [Abstract] [Full Text] [Related]

  • 11. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
    Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T.
    J Endocrinol; 2012 Sep 17; 214(3):381-7. PubMed ID: 22761275
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice.
    Ma M, Hasegawa Y, Koibuchi N, Toyama K, Uekawa K, Nakagawa T, Lin B, Kim-Mitsuyama S.
    Cardiovasc Diabetol; 2015 May 20; 14():54. PubMed ID: 25986579
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Tiwari A.
    Curr Opin Investig Drugs; 2009 Oct 20; 10(10):1091-104. PubMed ID: 19777398
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Knockdown of LncRNA-H19 Ameliorates Kidney Fibrosis in Diabetic Mice by Suppressing miR-29a-Mediated EndMT.
    Shi S, Song L, Yu H, Feng S, He J, Liu Y, He Y.
    Front Pharmacol; 2020 Oct 20; 11():586895. PubMed ID: 33324218
    [Abstract] [Full Text] [Related]

  • 19. Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis.
    Srivastava SP, Shi S, Kanasaki M, Nagai T, Kitada M, He J, Nakamura Y, Ishigaki Y, Kanasaki K, Koya D.
    Sci Rep; 2016 Jul 18; 6():29884. PubMed ID: 27425816
    [Abstract] [Full Text] [Related]

  • 20. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.
    Clin Ther; 2010 Jun 18; 32(6):1188-204. PubMed ID: 20637971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.